Emry Lloyd

Conference Coverage

Use of Pharmacogenomic Testing to Predict Bruton’s Tyrosine Kinase Inhibitor Treatment Intolerance

08/09/2023

Researchers conducted a study to determine whether cytochrome P450 polymorphisms can contribute to treatment intolerance in patients receiving Bruton’s tyrosine kinase inhibitors.

Researchers conducted a study to...

08/09/2023

Journal of Clinical Pathways

News

Do Medically Integrated Pharmacies Reduce the Abandonment Rate of Oral Anticancer Medications?

10/30/2023

Emry Lloyd ;

Dr Doshi and colleagues measured the impact of medically integrated pharmacies on prescription medication abandonment rates.

Dr Doshi and colleagues measured...

10/30/2023

Journal of Clinical Pathways

News

Targeted Medicine and Biological Therapies Fighting Type 2 Inflammation in Patients With Asthma

12/20/2023

Emry Lloyd ;

In a recent review, Imran Howell, University of Oxford, UK, and colleagues sought to understand the impact of biological therapies and targeted medicines for type 2 inflammation in patients with asthma.

In a recent review, Imran...

12/20/2023

First Report Managed Care

News

New Legislation Provides Protection for Residents Facing Unexplained Nursing Home Discharges

01/18/2024

Emry Lloyd ;

California passed legislation mandating nursing homes provide evicted residents with a documented reason for discharge. This measure aims to ensure that residents have the appropriate paperwork to initiate an appeal.

California passed legislation...

01/18/2024

Annals of Long-Term Care

News

FDA Approves Dostarlimab-gxly With Chemotherapy for Patients With Endometrial Cancer

08/16/2023

Emry Lloyd ;

In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.

In July 2023, the FDA approved...

08/16/2023

Journal of Clinical Pathways

News

How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?

10/27/2023

Emry Lloyd ;

Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.

Katherine Baker, MD, and...

10/27/2023

Journal of Clinical Pathways

News

Comparative Effectiveness for Bronchodilator Responsiveness Testing

02/09/2024

Emry Lloyd ;

A new study compares the efficacy of salbutamol administration via a nebulizer vs a metered-dose inhaler with a spacer for bronchodilator responsiveness testing.

A new study compares the...

02/09/2024

First Report Managed Care

News

Bayer AG Moves to Phase 2 Clinical Trial for New Gene Therapy for Parkinson Disease

01/24/2024

Emry Lloyd ;

Bayer AG receives approval to proceed with a phase 2 clinical trial for its gene therapy for patients with Parkinson disease.

Bayer AG receives approval to...

01/24/2024

Annals of Long-Term Care

Conference Coverage

Analysis Finds That Commuting Distance Affects Equitable Access to and Enrollment in US Cancer Clinical Trials

06/05/2023

Emry Lloyd ;

In an abstract presented at ASCO 2023, researchers found that one-way commuting distance to US-based cancer trial sites is a key barrier to socioeconomically equitable clinical trial enrollment.

In an abstract presented at ASCO...

06/05/2023

Journal of Clinical Pathways

News

Analysis of the Impact Bruton Tyrosine Kinase Inhibitor Discontinuation Has After First- or Second-Line Therapy

08/22/2023

Emry Lloyd ;

Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.

Researchers studied data on the...

08/22/2023

Journal of Clinical Pathways